Tuberc Respir Dis > Volume 83(3); 2020 > Article |
|
Authors’ Contributions
Conceptualization: Kim JS, Lee SS, Park JS, Kang JY. Methodology: Kim JS, Min J, Kim HW, Ko Y. Formal analysis: Kim JS, Min J, Lee J, Oh JY. Data curation: Kim JS, Lee J. Writing - original draft preparation: Min J, Kim JS, Kim HW, Ko Y, Oh JY. Writing - review and editing: Min J, Lee SS, Park JS, Kang JY, Lee J. Approval of final manuscript: all authors.
† Data are from the TB surveillance newsletter published by the Korea Centers for Disease Control and Prevention10. The denominator excludes the multidrug-resistant TB cases.
‡ This indicator is calculated by dividing the number of new cases managed by the national PPM TB control project by the number of new notification cases in South Korea in each calendar year.
* Smear-positive pulmonary TB cases are defined by International Classification of Diseases (ICD)-10 codes (A15.00 or A15.01) and positive results of sputum AFB smear tests. Patients with rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) were excluded. Patients who ‘transferred out’ to another treatment unit, returned to their home country, and died of non-TB-related causes were excluded.
† Initial standard regimens of anti-TB treatment include HREZ, HRE, HEZ+Rfb, or HE+Rfb (H, isoniazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; Rfb, rifabutin).
‡ Patients with isoniazid-resistant TB, RR-TB, and MDR-TB were excluded. Patients whose data regarding anti-TB drugs were not entered in the Korean National TB Surveillance System were excluded. Patients registered as ‘treatment after failure’ were excluded.
Jinsoo Min
https://orcid.org/0000-0001-6091-518X
Ju Sang Kim
https://orcid.org/0000-0002-4433-231X
Ministry of Health and Welfare
https://doi.org/10.13039/501100003625
Medical Insurance and National Tuberculosis Control System in Korea1972 March;19(1)